![](https://www.inotrem.com/wp-content/uploads/2020/01/INOTREM-NS.png)
Inotrem expands Series B financing to €58 Million with a mix of Equity and Debt, adding new investors Fountain Healthcare Partners, Kreos and Bpifrance
Paris, February 11th, 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and